Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaijin Jieyu Anshen Tablets
- Lead developer
- Grand Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
GPN01360 (Chaijin Jieyu Anshen Tablets) is an innovative traditional Chinese medicine (Class 1.1 TCM innovative drug) being developed by Grand Pharmaceutical Group (via its subsidiary Grand Beilin Pharmaceutical) and originally developed by Hunan University of Chinese Medicine for the treatment of depression, specifically depression with liver-qi stagnation and spleen deficiency pattern. Based on the classic ancient formula Xiaoyao San, the formulation was optimized through modern pharmacology and clinical research. It contains 12 herbal ingredients, including Chaihu (Bupleurum), Yujin (Curcuma), and Foshou (Finger Citron). In clinical trials, GPN01360 has demonstrated favorable efficacy and safety in improving depressive symptoms, relieving anxiety and insomnia, and regulating spleen and stomach function.
- Other names
- Chai Jin Jieyu Anshen TabletsChaijin Jieyu AnshenChaijin Jieyu Anshen Pian柴金解郁安神片
02
Targets
CFL1 (Cofilin-1)CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)DLG4 (Disks Large Homolog 4)GRIN2A (NMDA receptor subunit 2A)GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)HDAC5 (Histone deacetylase 5)MK2 (Mitogen-activated protein kinase-activated protein kinase 2)MEF2C
Beyond the preview
Go deeper on Chaijin Jieyu Anshen Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chaijin Jieyu Anshen Tablets.
Work on Chaijin Jieyu Anshen Tablets? Claim this page to correct or add information. Claim this page